Literature DB >> 16460628

Management of Dupuytren's disease--clear advice for an elusive condition.

A Bayat1, D A McGrouther.   

Abstract

Dupuytren's disease is a progressive fibroproliferative disorder of an unknown origin affecting the hands causing permanent flexion contracture of the digits. Significant risk factors for development of Dupuytren's disease include old age, male sex, white northern European extraction, presence of positive family history of Dupuytren's disease, and diabetes mellitus. The disease also seems to deteriorate rapidly in those cases showing young age of onset and additional fibromatosis affecting the back of the hands, soles of the feet and the penis. Although there is no cure, patients with Dupuytren's disease of the hand may gain a significant functional benefit following surgical improvement or correction of the deformity. With realistic expectations, timely and appropriate surgical technique in a specialist centre, and attention to postoperative recovery and rehabilitation (occupational therapy and physiotherapy support), a beneficial outcome can be achieved in most cases.

Entities:  

Mesh:

Year:  2006        PMID: 16460628      PMCID: PMC1963648          DOI: 10.1308/003588406X83104

Source DB:  PubMed          Journal:  Ann R Coll Surg Engl        ISSN: 0035-8843            Impact factor:   1.891


  29 in total

1.  The injection of nodules of Dupuytren's disease with triamcinolone acetonide.

Authors:  L D Ketchum; T K Donahue
Journal:  J Hand Surg Am       Date:  2000-11       Impact factor: 2.230

2.  Increased total mortality and cancer mortality in men with Dupuytren's disease: a 15-year follow-up study.

Authors:  Kristján G Gudmundsson; Reynir Arngrímsson; Nikulás Sigfússon; Thorbjörn Jónsson
Journal:  J Clin Epidemiol       Date:  2002-01       Impact factor: 6.437

3.  An objective method to evaluate the risk of recurrence and extension of Dupuytren's disease.

Authors:  Y Abe; T Rokkaku; S Ofuchi; S Tokunaga; K Takahashi; H Moriya
Journal:  J Hand Surg Br       Date:  2004-10

Review 4.  Dupuytren's disease.

Authors:  Alan J Thurston
Journal:  J Bone Joint Surg Br       Date:  2003-05

5.  [Radiotherapy of early stage Dupuytren disease. Long-term results after a median follow-up period of 10 years].

Authors:  B Adamietz; L Keilholz; J Grünert; R Sauer
Journal:  Strahlenther Onkol       Date:  2001-11       Impact factor: 3.621

6.  Genetic susceptibility to dupuytren disease: association of Zf9 transcription factor gene.

Authors:  Ardeshir Bayat; J Stewart Watson; John K Stanley; Mark W J Ferguson; William E R Ollier
Journal:  Plast Reconstr Surg       Date:  2003-06       Impact factor: 4.730

7.  Epidemiology of Dupuytren's disease: clinical, serological, and social assessment. The Reykjavik Study.

Authors:  K G Gudmundsson; R Arngrímsson; N Sigfússon; A Björnsson; T Jónsson
Journal:  J Clin Epidemiol       Date:  2000-03-01       Impact factor: 6.437

8.  Collagen as a clinical target: nonoperative treatment of Dupuytren's disease.

Authors:  Marie A Badalamente; Lawrence C Hurst; Vincent R Hentz
Journal:  J Hand Surg Am       Date:  2002-09       Impact factor: 2.230

9.  Functional benefit of Dupuytren's surgery.

Authors:  R Sinha; T R Cresswell; R Mason; I Chakrabarti
Journal:  J Hand Surg Br       Date:  2002-08

10.  A prospective randomised clinical trial of the intra-operative use of 5-fluorouracil on the outcome of dupuytren's disease.

Authors:  N W Bulstrode; M Bisson; B Jemec; A L Pratt; D A McGrouther; A O Grobbelaar
Journal:  J Hand Surg Br       Date:  2004-02
View more
  39 in total

1.  Aggressive Dupuytren's diathesis in a young woman.

Authors:  Ivan Couto-Gonzalez; Beatriz Brea-Garcia; Antonio Taboada-Suárez; Eduardo González-Álvarez
Journal:  BMJ Case Rep       Date:  2010-09-20

2.  Postoperative management of Dupuytren's disease with topical nitroglycerin.

Authors:  Patrick I Emelife; Russell E Kling; Ronit Wollstein
Journal:  Can J Plast Surg       Date:  2012

3.  T2 signal intensity as an imaging biomarker for patients with superficial Fibromatoses of the hands (Dupuytren's disease) and feet (Ledderhose disease) undergoing definitive electron beam irradiation.

Authors:  James S Banks; Aaron H Wolfson; Ty K Subhawong
Journal:  Skeletal Radiol       Date:  2017-10-30       Impact factor: 2.199

4.  Connective tissue diseases: A nonsurgical therapy for Dupuytren disease.

Authors:  Ardeshir Bayat
Journal:  Nat Rev Rheumatol       Date:  2010-01       Impact factor: 20.543

5.  Revised Tubiana's staging system for assessment of disease severity in Dupuytren's disease-preliminary clinical findings.

Authors:  Sandip Hindocha; John K Stanley; James Stewart Watson; Ardeshir Bayat
Journal:  Hand (N Y)       Date:  2007-09-11

6.  Safety and Effectiveness of Percutaneous Needle Fasciotomy for Dupuytren's Disease in the Palm.

Authors:  Muhammad Mansha; Darren Flynn; John Stothard
Journal:  J Hand Microsurg       Date:  2017-08-08

7.  Identification of mesenchymal stem cells in perinodular fat and skin in Dupuytren's disease: a potential source of myofibroblasts with implications for pathogenesis and therapy.

Authors:  Syed Amir Iqbal; Christopher Manning; Farhatullah Syed; Venkatesh Kolluru; Mike Hayton; Stewart Watson; Ardeshir Bayat
Journal:  Stem Cells Dev       Date:  2011-07-19       Impact factor: 3.272

8.  Carpal tunnel syndrome in pregnancy.

Authors:  G G Nicholas; R B Noone; W P Graham
Journal:  Hand       Date:  1971-03

9.  Epidemiological evaluation of Dupuytren's disease incidence and prevalence rates in relation to etiology.

Authors:  Sandip Hindocha; Duncan Angus McGrouther; Ardeshir Bayat
Journal:  Hand (N Y)       Date:  2009-01-15

10.  Differential gene expression analysis of subcutaneous fat, fascia, and skin overlying a Dupuytren's disease nodule in comparison to control tissue.

Authors:  Barbara Shih; Jason J Brown; Daniel J Armstrong; Tommy Lindau; Ardeshir Bayat
Journal:  Hand (N Y)       Date:  2009-01-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.